GSE101644

Primary melanoma cell lines vary in glycolytic activity

Some patients with metastatic melanoma respond very well to adoptive T-cell therapy (ACT) based on re-infusion of autologous, ex vivo-expanded tumor-infiltrating T lymphocytes (TILs) plus interleukin-2 (IL-2). However, responses are highly variable. We found that glycolysis in primary melanoma tumor cell lines, as measured by metabolic assays or expression of glycolysis genes, was strongly associated with clinical resistance of the corresponding patients' tumor to ACT.

Provenance — who produced it, who reused it

Linked to 1 papers in the literature. Roles are inferred factual signals (who deposited the data vs who reused it), with counts — never a judgement about any author.

Standardized, field-standard QC computed by touching the data — every metric states how it was obtained

measured = computed from the data · extrapolated/reported = derived or from the repository · dq-1.0 · provisional — verify independently